Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Contract Assets and Liabilities (Details)

v3.21.1
Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract assets $ 2,014 $ 1,643
Long-term pharma contract assets 355 290
Total pharma contract assets 2,369 1,933
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 182 185
Long-term pharma capitalized commissions 1,020 970
Total pharma capitalized commissions 1,202 1,155
Contract with Customer, Liability [Abstract]    
Current pharma contract liabilities 3,992 4,029
Long-term pharma contract liabilities 705 712
Total pharma contract liabilities $ 4,697 $ 4,741